(CercleFinance.com) – Portzamparc maintains its recommendation to ‘buy’ on Theradiag, pointing out that the manufacturer of in vitro diagnostic systems came close to profitability in the first half.
In a study released on Monday, the analyst points out that the company’s net result, which stands at -56,000 euros over the first six months of the year, would have been positive up to +10,000 euros in the event of credit. constant research tax.
According to Portzamparc, this ‘near-profitable’ first half suggests a positive result in the second half thanks to the steady growth of the company’s turnover, which according to him provides the fuel necessary to achieve this breakeven point.
‘Some adjustments on the side of operating expenses will probably be necessary to switch significantly in profitability’, however, estimates the design office in its note.
Portzamparc says it has adjusted its price target on the title, which it reduces from 2.4 to 2.3 euros, recalling that its scenario so far anticipated profitability from the first half of the 2022 financial year.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
